{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:14:01Z","timestamp":1759058041469,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.psym.2020.08.011","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T11:24:49Z","timestamp":1600169089000},"page":"115-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune Checkpoint Inhibitor\u2013Associated Autoimmune Encephalitis"],"prefix":"10.1016","volume":"62","author":[{"given":"Nichakarn","family":"Yordduangjun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Dishion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psym.2020.08.011_bib1","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.psym.2020.08.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.psym.2020.08.011_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.psym.2020.08.011_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.psym.2020.08.011_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J\u00a0Neurooncol"},{"author":"Postow","key":"10.1016\/j.psym.2020.08.011_bib6"},{"key":"10.1016\/j.psym.2020.08.011_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.psym.2020.08.011_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2013.3216","article-title":"Frequency and characteristics of isolated psychiatric episodes in anti\u2013N-methyl-d-aspartate receptor encephalitis","volume":"70","author":"Kayser","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.psym.2020.08.011_bib9","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.psym.2020.08.011_bib10","doi-asserted-by":"crossref","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.psym.2020.08.011_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.psym.2020.08.011_bib12","unstructured":"Guidon AC. Which neurological problems are caused by immunotherapy? In: Reynolds KL, Cohen JV, Zubiri L, Stern TA, (eds) Facing immunotherapy: a guide for patients and their families, 1st ed. Boston, MA: Massachusetts General Hospital Psychiatry Academy; 2020. p.74"},{"key":"10.1016\/j.psym.2020.08.011_bib13","doi-asserted-by":"crossref","first-page":"576980","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A\u00a0case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes","volume":"334","author":"Gill","year":"2019","journal-title":"J\u00a0Neuroimmunol"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318220302450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318220302450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:29:33Z","timestamp":1758688173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318220302450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0033318220302450"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2020.08.011","relation":{},"ISSN":["2667-2960"],"issn-type":[{"type":"print","value":"2667-2960"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Associated Autoimmune Encephalitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psym.2020.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}